Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Cooper City, Florida Clinical Trials

A listing of Cooper City, Florida clinical trials actively recruiting patient volunteers.

RESULTS

Found (14) clinical trials

A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (pPCV) in Adults (pPCV-001)

This Phase 1 and Phase 2 study will evaluate the safety, tolerability and immunogenicity of polyvalent pneumococcal conjugate vaccine (pPCV) when administered to adults. Phase 1 has no formal hypothesis. The primary hypotheses for Phase 2 are: pPCV is noninferior to Pneumovax23 as measured by the serotype-specific opsonophagocytic activity (OPA) …

Phase

2.38 miles

Learn More »

Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease

In the context of the proposed study, adipose derived stem cells (ASC) constitute an autologous cell product that is delivered to the patient via intra-venous injection. In this study, we propose to investigate the immunosuppressive potential of the non-manipulated non-cultured stromal vascular fraction obtained via liposuction. Endpoints will be measured …

Phase

3.91 miles

Learn More »

Combination Study of SV-BR-1-GM in Combination With INCMGA00012 and Epacadostat

This is an open-label, single arm study of the SV-BR-1-GM regimen in combination with INCMGA00012 and epacadostat in patients with metastatic or locally recurrent breast cancer who have failed at least two lines of therapy. Patients will receive the SV-BR-1-GM regimen with combination immunotherapy. There will be an initial evaluation …

Phase

4.73 miles

Learn More »

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

A Phase 1-2, multicenter, open-label study of various ASTX727 LD doses and schedules to assess the safety, pharmacodynamics (PD), pharmacokinetics (PK), and hematologic response in subjects with IPSS risk category of low-risk or Intermediate-1 MDS. The study will be conducted in 2 phases. Phase 1: In Stage A, subjects will …

Phase

4.73 miles

Learn More »

Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors RET Fusion-Positive Solid Tumors and Medullary Thyroid Cancer

This is an open-label, multi-center Phase 1/2 study in patients with advanced solid tumors, including RET fusion-positive solid tumors, MTC, and other tumors with RET activation. The trial will be conducted in 2 parts: phase 1 (dose escalation) and phase 2 (dose expansion). Patients with advanced cancer are eligible if …

Phase

5.28 miles

Learn More »

Descartes-11 in Multiple Myeloma

This Phase I/2 study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.

Phase

5.28 miles

Learn More »

A Dose Ranging Study Evaluating Efficacy and Safety of NI-03

The primary objective of the Single-Dose Phase is to assess the pharmacokinetics (PK) and safety of single doses of NI-03 when administered at doses of 100 mg, 200 mg or 300 mg to subjects with chronic pancreatitis. The primary objective of the Double-Blind Phase of the study is to determine …

Phase

5.69 miles

Learn More »

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements

In Phase 2, study subjects will be enrolled into 6 distinct expansion (EXP) cohorts: EXP-1: ROS1 TKI-nave ROS1+ NSCLC. Up to one prior line of chemotherapy OR immunotherapy is allowed EXP-2: 1 Prior ROS1 TKI AND 1 Platinum-based Chemotherapy ROS1+ NSCLC. Disease progression, or intolerant to one prior line of …

Phase

5.69 miles

Learn More »

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

This is a Phase 1/2, open-label, non-comparative, multicenter, multi-arm study of the Wilms Tumor-1 (WT1)-targeting multivalent heteroclitic peptide immunotherapeutic vaccine galinpepimut-S in combination with the programmed death-1 (PD1) inhibitor pembrolizumab in patients with selected advanced cancers. This study will assess the efficacy and safety of galinpepimut-S and pembrolizumab and investigate …

Phase

5.69 miles

Learn More »